LOS ANGELES, CA / ACCESSWIRE / August 30, 2022 / The Schall Legislation Agency, a nationwide shareholder rights litigation agency, declares that it’s investigating claims on behalf of buyers of EyePoint Prescribed drugs, Inc. (“EyePoint” or “the Firm”) (NASDAQ:EYPT) for violations of the securities legal guidelines.
The investigation focuses on whether or not the Firm issued false and/or deceptive statements and/or didn’t disclose info pertinent to buyers. EyePoint disclosed after market hours on August 30, 2022, that it had acquired a subpoena from the US Legal professional’s Workplace for the District of Massachusetts. The subpoena demanded paperwork overlaying the Firm’s gross sales practices for its postoperative irritation remedy, DEXYCU. Primarily based on this information, shares of EyePoint fell sharply in after hours buying and selling.
In case you are a shareholder who suffered a loss, click on right here to take part.
We additionally encourage you to contact Brian Schall of the Schall Legislation Agency, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to debate your rights freed from cost. You can too attain us by the agency’s web site at www.schallfirm.com, or by e-mail at [email protected].
The category on this case has not but been licensed, and till certification happens, you aren’t represented by an lawyer. When you select to take no motion, you possibly can stay an absent class member.
The Schall Legislation Agency represents buyers around the globe and makes a speciality of securities class motion lawsuits and shareholder rights litigation.
This press launch could also be thought of Legal professional Promoting in some jurisdictions below the relevant legislation and guidelines of ethics.
The Schall Legislation Agency
Brian Schall, Esq.
SOURCES: The Schall Legislation Agency
View supply model on accesswire.com:
https://www.accesswire.com/714114/INVESTIGATION-ALERT-The-Schall-Legislation-Agency-Encourages-Traders-in-EyePoint-Prescribed drugs-Inc-with-Losses-of-100000-to-Contact-the- Agency